Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$221.17 -0.6%	$237.59	$146.12 ▼ $251.71	$535.63B	0.27	7.86 million shs	5.46 million shs
LLY Eli Lilly and Company	$948.01 -2.8%	$943.90	$623.78 ▼ $1,133.95	$918.16B	0.48	3.39 million shs	3.24 million shs
MRK Merck & Co., Inc.	$111.26 -0.9%	$117.07	$73.31 ▼ $125.14	$277.36B	0.18	9.56 million shs	5.71 million shs
PFE Pfizer	$25.65 -3.1%	$27.14	$21.97 ▼ $28.75	$150.92B	0.35	36.09 million shs	37.42 million shs
ZTS Zoetis	$82.80 -5.2%	$118.49	$81.10 ▼ $172.23	$36.73B	0.87	4.93 million shs	17.18 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	0.00%	-3.38%	-7.73%	-7.46%	+41.43%
LLY Eli Lilly and Company	0.00%	+4.03%	+2.37%	-7.78%	+25.47%
MRK Merck & Co., Inc.	0.00%	+2.65%	-8.95%	-7.95%	+41.89%
PFE Pfizer	0.00%	-1.00%	-3.62%	-2.80%	+16.24%
ZTS Zoetis	0.00%	-24.42%	-27.30%	-31.72%	-44.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$221.17 -0.6%	$237.59	$146.12 ▼ $251.71	$535.63B	0.27	7.86 million shs	5.46 million shs
LLY Eli Lilly and Company	$948.01 -2.8%	$943.90	$623.78 ▼ $1,133.95	$918.16B	0.48	3.39 million shs	3.24 million shs
MRK Merck & Co., Inc.	$111.26 -0.9%	$117.07	$73.31 ▼ $125.14	$277.36B	0.18	9.56 million shs	5.71 million shs
PFE Pfizer	$25.65 -3.1%	$27.14	$21.97 ▼ $28.75	$150.92B	0.35	36.09 million shs	37.42 million shs
ZTS Zoetis	$82.80 -5.2%	$118.49	$81.10 ▼ $172.23	$36.73B	0.87	4.93 million shs	17.18 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	0.00%	-3.38%	-7.73%	-7.46%	+41.43%
LLY Eli Lilly and Company	0.00%	+4.03%	+2.37%	-7.78%	+25.47%
MRK Merck & Co., Inc.	0.00%	+2.65%	-8.95%	-7.95%	+41.89%
PFE Pfizer	0.00%	-1.00%	-3.62%	-2.80%	+16.24%
ZTS Zoetis	0.00%	-24.42%	-27.30%	-31.72%	-44.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JNJ Johnson & Johnson	2.67	Moderate Buy	$252.48	14.15% Upside
LLY Eli Lilly and Company	2.87	Moderate Buy	$1,218.33	28.51% Upside
MRK Merck & Co., Inc.	2.68	Moderate Buy	$128.18	15.21% Upside
PFE Pfizer	2.23	Hold	$28.74	12.05% Upside
ZTS Zoetis	2.40	Hold	$141.25	70.59% Upside

Current Analyst Ratings Breakdown

Latest ZTS, LLY, JNJ, MRK, and PFE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/8/2026	ZTS Zoetis	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$130.00 ➝ $99.00
5/8/2026	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$105.00
5/8/2026	ZTS Zoetis	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$190.00 ➝ $130.00
5/7/2026	LLY Eli Lilly and Company	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target		$880.00 ➝ $900.00
5/6/2026	PFE Pfizer	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
5/6/2026	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$125.00
5/5/2026	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$1,183.00
5/4/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
5/4/2026	LLY Eli Lilly and Company	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$1,325.00
5/4/2026	LLY Eli Lilly and Company	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,350.00 ➝ $1,400.00
5/1/2026	MRK Merck & Co., Inc.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)

(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JNJ Johnson & Johnson	$94.19B	5.65	$14.03 per share	15.76	$33.73 per share	6.56
LLY Eli Lilly and Company	$65.18B	13.70	$24.45 per share	38.78	$33.13 per share	28.61
MRK Merck & Co., Inc.	$65.01B	4.23	$11.32 per share	9.83	$18.60 per share	5.98
PFE Pfizer	$62.58B	2.34	$4.26 per share	6.02	$15.86 per share	1.62
ZTS Zoetis	$9.47B	3.68	$7.18 per share	11.54	$7.56 per share	10.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JNJ Johnson & Johnson	$26.80B	$8.65	25.57	17.58	2.18	21.83%	32.60%	13.29%	7/15/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$28.15	33.68	21.53	1.07	34.98%	105.77%	23.76%	N/A
MRK Merck & Co., Inc.	$18.25B	$3.55	31.34	11.39	2.53	13.59%	27.55%	10.73%	N/A
PFE Pfizer	$7.77B	$1.31	19.58	8.97	N/A	11.83%	19.44%	8.41%	N/A
ZTS Zoetis	$2.67B	$6.03	13.73	10.94	1.34	27.80%	61.97%	18.83%	N/A

Latest ZTS, LLY, JNJ, MRK, and PFE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2026	Q1 2026	ZTS Zoetis	$1.60	$1.53	-$0.07	$1.42	$2.30 billion	$2.26 billion
5/5/2026	Q1 2026	PFE Pfizer	$0.7220	$0.75	+$0.0280	$0.47	$13.84 billion	$14.45 billion
4/30/2026	Q1 2026	LLY Eli Lilly and Company	$6.97	$8.55	+$1.58	$8.26	$17.82 billion	$19.80 billion
4/30/2026	Q1 2026	MRK Merck & Co., Inc.	-$1.47	-$1.28	+$0.19	-$1.72	$15.85 billion	$16.29 billion
4/14/2026	Q1 2026	JNJ Johnson & Johnson	$2.68	$2.70	+$0.02	$2.14	$23.60 billion	$24.06 billion
2/12/2026	Q4 2025	ZTS Zoetis	$1.40	$1.48	+$0.08	$1.37	$2.36 billion	$2.39 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
JNJ Johnson & Johnson	$5.20	2.35%	+5.25%	60.12%	64 Years
LLY Eli Lilly and Company	$6.92	0.73%	+15.18%	24.58%	11 Years
MRK Merck & Co., Inc.	$3.40	3.06%	+5.75%	95.77%	14 Years
PFE Pfizer	$1.72	6.71%	-13.20%	131.30%	16 Years
ZTS Zoetis	$2.12	2.56%	+20.11%	35.16%	14 Years

Latest ZTS, LLY, JNJ, MRK, and PFE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/22/2026	PFE Pfizer	quarterly	$0.43	6.71%	5/8/2026	5/8/2026	6/12/2026
5/4/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.72%	5/15/2026	5/15/2026	6/10/2026
4/14/2026	JNJ Johnson & Johnson	quarterly	$1.34	2.23%	5/26/2026	5/26/2026	6/9/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JNJ Johnson & Johnson	0.46	1.03	0.77
LLY Eli Lilly and Company	1.26	1.50	1.10
MRK Merck & Co., Inc.	1.02	1.30	1.30
PFE Pfizer	0.67	1.25	0.87
ZTS Zoetis	2.71	3.03	1.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JNJ Johnson & Johnson	69.55%
LLY Eli Lilly and Company	82.53%
MRK Merck & Co., Inc.	76.07%
PFE Pfizer	68.36%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
JNJ Johnson & Johnson	0.16%
LLY Eli Lilly and Company	0.14%
MRK Merck & Co., Inc.	0.17%
PFE Pfizer	0.62%
ZTS Zoetis	0.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JNJ Johnson & Johnson	138,200	2.41 billion	2.40 billion	Optionable
LLY Eli Lilly and Company	50,000	941.74 million	940.42 million	Optionable
MRK Merck & Co., Inc.	75,000	2.47 billion	2.47 billion	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable
ZTS Zoetis	14,500	420.64 million	419.72 million	Optionable

ZTS, LLY, JNJ, MRK, and PFE Headlines

Recent News About These Companies

Truist Financial Corp Has $10.08 Million Position in Zoetis Inc. $ZTS

22 minutes ago | marketbeat.com

Generali Asset Management SPA SGR Decreases Position in Zoetis Inc. $ZTS

1 hour ago | marketbeat.com

Zoetis (NYSE:ZTS) Price Target Cut to $130.00 by Analysts at JPMorgan Chase & Co.

May 8 at 3:26 PM | marketbeat.com

Zoetis Inc. $ZTS Holdings Lowered by Premier Fund Managers Ltd

May 8 at 6:42 AM | marketbeat.com

Zoetis Inc. $ZTS Shares Sold by Sumitomo Mitsui DS Asset Management Company Ltd

May 8 at 6:02 AM | marketbeat.com

Zoetis Inc. $ZTS Shares Sold by Crestwood Advisors Group LLC

May 8 at 4:31 AM | marketbeat.com

Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Zoetis Inc.

May 7 at 9:56 PM | prnewswire.com

Zoetis Earnings Call Balances Strength And Strain

May 7 at 8:30 PM | tipranks.com

Promising Medical Stocks To Research - May 7th

May 7 at 3:46 PM | marketbeat.com

Why Zoetis Shares Plummeted Today

May 7 at 3:10 PM | fool.com

Zoetis Inc. (ZTS) Q1 2026 Earnings Call Transcript

May 7 at 3:05 PM | seekingalpha.com

US Pet Care Demand Is Weak - Zoetis Cuts Outlook

May 7 at 1:50 PM | benzinga.com

Zoetis Stock (ZTS) Opinions on Q1 Earnings Miss and Guidance Cut

May 7 at 1:50 PM | quiverquant.comQ

Zoetis Q1 Earnings Lag Estimates, 2026 View Cut, Stock Down

May 7 at 1:50 PM | zacks.com

US Pet Care Demand Is Weak - Zoetis Cuts Outlook

May 7 at 1:33 PM | benzinga.com

Zoetis (ZTS) Stock Plummets 20% Following Disappointing Q1 Results and Guidance Cut

May 7 at 12:31 PM | blockonomi.com

Zoetis Is Today's Worst S&P 500 Stock. Here's Why.

May 7 at 12:03 PM | barrons.com

Zoetis (ZTS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

May 7 at 10:31 AM | zacks.com

Zoetis (NYSE:ZTS) Shares Gap Down After Earnings Miss

May 7 at 10:19 AM | marketbeat.com

Zoetis (ZTS) Misses Q1 Earnings and Revenue Estimates

May 7 at 9:56 AM | zacks.com

Zoetis Inc. 2026 Q1 - Results - Earnings Call Presentation

May 7 at 9:01 AM | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ZTS, LLY, JNJ, MRK, and PFE Company Descriptions

Johnson & Johnson NYSE:JNJ

$221.17 -1.34 (-0.60%)

Closing price 05/8/2026 03:59 PM Eastern

Extended Trading

$221.25 +0.08 (+0.04%)

As of 05/8/2026 07:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company NYSE:LLY

$948.01 -26.95 (-2.76%)

Closing price 05/8/2026 03:59 PM Eastern

Extended Trading

$950.10 +2.09 (+0.22%)

As of 05/8/2026 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. NYSE:MRK

$111.26 -1.05 (-0.93%)

Closing price 05/8/2026 03:59 PM Eastern

Extended Trading

$111.84 +0.59 (+0.53%)

As of 05/8/2026 07:52 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer NYSE:PFE

$25.65 -0.83 (-3.15%)

Closing price 05/8/2026 03:59 PM Eastern

Extended Trading

$25.68 +0.03 (+0.11%)

As of 05/8/2026 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Zoetis NYSE:ZTS

$82.80 -4.51 (-5.17%)

Closing price 05/8/2026 03:59 PM Eastern

Extended Trading

$82.82 +0.02 (+0.02%)

As of 05/8/2026 07:59 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZTS, LLY, JNJ, MRK, and PFE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZTS, LLY, JNJ, MRK, and PFE Earnings

Compare Dividends

Latest ZTS, LLY, JNJ, MRK, and PFE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZTS, LLY, JNJ, MRK, and PFE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZTS, LLY, JNJ, MRK, and PFE Company Descriptions

Johnson & Johnson NYSE:JNJ

Eli Lilly and Company NYSE:LLY

Merck & Co., Inc. NYSE:MRK

Pfizer NYSE:PFE

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools